Status:
RECRUITING
Increasing Physical Activity Through Social Support and Stress Resilience
Lead Sponsor:
Arizona State University
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Healthy
Subjective Cognitive Decline (SCD)
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn the effects of technology enhancements when combined with basic education, goal-setting, and self-monitoring to increase physical activity among older adult...
Eligibility Criteria
Inclusion
- Aged 60 years or older
- Living alone and community dwelling
- Engaging in 60 minutes or less per week of self-reported moderate-to-vigorous physical activity at screening (based on Exercise Vital Sign Questionnaire)
- Self-reported decline in cognitive functioning
- Self-reported ownership of/willingness to use a smartphone with an iOS or Android operating system (necessary for participants to track their activity using a wearable activity monitor).
- Able to read and speak in English. We hope to offer the intervention in Spanish in the future; however, currently, the study materials are only available in English, and participation will require ability to read and respond to study materials.
Exclusion
- Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a physician's note is provided
- Resting blood pressure greater than 200/110 mmHG as assessed at the baseline study assessment (unless a physician's note is provided)
- Plans to relocate out of metropolitan Phoenix, Arizona area in the next 6 months
- Participation in another physical activity, nutrition or weight loss program at time of screening or at any time during the intervention
- Individuals with mild cognitive impairment (MCI), as determined by either a self-report of receiving a diagnosis of MCI from a health care provider or as assessed by the Telephone-Montreal Cognitive Assessment (T-MoCA) at the Baseline Session. A score \< 19 is an exclusion criterion.
- Individuals with neurodegenerative (e.g., dementia), developmental (e.g., autism), neurologic (e.g., Parkinson's, epilepsy), or major psychiatric (e.g., bipolar, schizophrenia) diagnoses
- Being previously prescribed one of the 5 approved Alzheimer's medications, including: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), Memantine (Namenda), Memantine + Donepezil (Namzaric)
- Score of 9 or higher on the 15-item Geriatric Depression Scale (GDS) at the Baseline Session \[scores of 9 and higher are indicative of moderate to severe depression\]
- Currently taking 2 or more anti-depression medications
- History of stroke
- Incarcerated individuals (i.e., Prisoners)
Key Trial Info
Start Date :
June 23 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT06896825
Start Date
June 23 2025
End Date
July 1 2026
Last Update
July 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona State University
Phoenix, Arizona, United States, 85004